9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

计划入组 32 人 · 首次发布于 2021 年 8 月 18 日

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

首次发布于 2021 年 4 月 5 日

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

首次发布于 2021 年 11 月 11 日

glycogen synthase kinase 3 beta inhibitors (PsychoGenics)

N-aminoimidazole derivatives (Catholic University of Leuven)

Glycogen Synthase Kinase-3 Inhibitors(Boehringer Ingelheim)

Beta Bionics

Beta Innov

France

K-Group Beta, Inc.

United States

Elraglusib Shows Promise for Advanced Salivary Gland Carcinoma in Upcoming AACR Presentation

Actuate Therapeutics and Lantern Pharma Collaborate on AI-Driven Elraglusib Development

Actuate Therapeutics Raises $17.25 Million to Advance GSK-3β Inhibitor for Difficult-to-Treat Cancers